LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
LIPELLA PHARMACEUTICALS INC.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $2.27K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.6275 (−99.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
LIPELLA PHARMACEUTICALS INC. saw revenue fall 19.4% to $389.78K over the twelve months to Sep 30, 2025.
Revenue
$389.78K
-19.4% vs. a year earlier
Operating income
-$5.41M
TTM Q3 2025
EPS, diluted
-$2.42
TTM Q3 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2025
Valuation
- Market cap
- $2.27K
- P/E ratio
- –
- Price to sales
- 0.01
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $389.78K
- Net income
- -$5.33M
- EPS, diluted
- -$2.42
- Book value per share
- $0.33
- Diluted shares
- 5M
Five years at a glance
Fiscal years 2020 to 2024 and trailing twelve months, USD
Revenue
$389.78K-19.4% YoY
Operating income
-$5.41M
Net income
-$5.33M
EPS, diluted
-$2.42
Free cash flow
–
Reported periodTrailing twelve months